EU industry needs more supportive regulator as technologies blur
This article was originally published in Clinica
Executive Summary
The EU medical devices industry has long lamented the legal uncertainties surrounding products on the drug and device borderline. And such borderline products confusion - and frustrations for companies - are set to grow further as new legislation is implemented to take account of emerging technologies, including the forthcoming Human Tissue Engineering Product Regulation, writes Amanda Maxwell.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.